I joined the Virdee lab in summer 2026 to study MYCBP2, a large atypical E3 ubiquitin ligase that operates via an unprecedented, non-canonical RING-Cys-Relay (RCR) mechanism, catalysing hydroxy-directed (non-lysine) ubiquitination. My project aims to map the endogenous mammalian non-lysine ubiquitinome and to explore how MYCBP2's unusual activity might be redirected toward new therapeutic targets.

Prior to joining the MRC PPU, I completed my PhD at the Spanish National Cancer Research Centre (CNIO), under the supervision of Dr. Mariano Barbacid and Dr. Sara García-Alonso. I studied RAF1 biology in KRAS-driven cancers, exploring its targeted degradation as a therapeutic strategy. This project exposed me to degrader-based technologies, including PROTACs and dTAG-based degradation systems, and allowed me to work at the interface between cancer signalling and protein stability.